Lipoprav

Pravastatin sodium, the active ingredient in Lipoprav, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It treats hypercholesterolemia and helps prevent cardiovascular disease in adults.

GNH USA supplies Lipoprav as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipoprav belongs to the HMG‑CoA reductase inhibitor class and is used to manage disorders of lipid metabolism.

Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol levels. Primary hyperlipidemia: reduces total cholesterol and triglycerides. Cardiovascular disease prevention: decreases the risk of myocardial infarction and stroke in at‑risk patients.

Common Side Effects: - Headache - Muscle pain or cramps - Abdominal discomfort - Nausea - Diarrhea

Serious or Rare Side Effects: - Rhabdomyolysis (severe muscle breakdown) - Hepatotoxicity (elevated liver enzymes) - Severe allergic reactions, including anaphylaxis - Acute renal failure secondary to muscle breakdown - Thrombocytopenia

Before initiating therapy, clinicians should consider several safety measures.

Monitor liver function: obtain baseline and periodic liver enzyme tests. Assess renal function: adjust dose in patients with severe renal impairment. Evaluate for drug interactions: especially with CYP450 inhibitors and fibrates. Use caution in hypothyroid patients: increased risk of myopathy. Store at room temperature: keep in the original container, protect from moisture and light.

Pravastatin may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole) can raise pravastatin levels. - Co‑administration with gemfibrozil markedly increases risk of rhabdomyolysis. - Cyclosporine use significantly elevates pravastatin plasma concentrations.

Moderate Interactions (Monitor Closely): - Niacin may increase hepatic toxicity; monitor liver enzymes. - Antacids can reduce pravastatin absorption; assess lipid response. - Warfarin may require INR monitoring due to potential pharmacodynamic changes.